PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1550542
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1550542
Pneumococcal Vaccines Market, By Vaccine Type (Pneumococcal Conjugate Vaccines and Pneumococcal Polysaccharide Vaccines , By Target Population, By Route of Administration, By Distribution Channel, By Geography
Global pneumococcal vaccines market is estimated to be valued at USD 8.92 billion in 2024 and is expected to reach USD 12.51 billion by 2031, exhibiting a compound annual growth rate (CAGR) of 4.9% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 8.92 Bn |
| Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 To 2031 |
| Forecast Period 2024 to 2031 CAGR: | 4.90% | 2031 Value Projection: | US$ 12.51 Bn |
Global pneumococcal vaccines market growth is driven by factors such as rising incidence of pneumococcal diseases worldwide and growing immunization programs by various governments. Moreover, increasing awareness among people regarding pneumococcal vaccination can also drive the market growth. However, high costs associated with pneumococcal vaccines development and production can hamper the market growth. Ongoing research activities for developing affordable and effective vaccines can offer new opportunities in the near future.
Market Dynamics:
Global pneumococcal vaccines market growth is primarily driven by rising prevalence of pneumococcal pneumonia, meningitis, and other serious infections caused by Streptococcus pneumoniae bacteria worldwide. As per the World Health Organization (WHO), pneumonia is one of the top five causes of death in children under age of 5 years. Moreover, increasing government funding and initiatives to promote immunization programs through national immunization schedules can drive the market growth. However, high research, development and production costs of pneumococcal vaccines can hamper the market expansion. Ongoing clinical trials assessing the safety and efficacy of new multivalent pneumococcal formulations can drive the market growth. Emerging economies present significant opportunities for market players owing to improving healthcare infrastructures in these countries.
Key features of the study:
This report provides in-depth analysis of the global pneumococcal vaccines market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global pneumococcal vaccines market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer Inc., Merck & Co., GSK plc., and Sanofi
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global pneumococcal vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Detailed Segmentation-
- By Vaccine Type
- Pneumococcal Conjugate Vaccines (PCVs)
- PCV13 (Prevnar 13/Prevenar 13)
- PCV10 (Synflorix)
- PCV7 (Prevnar/Prevenar)
- Pneumococcal Polysaccharide Vaccines (PPVs)
- PPSV23 (Pneumovax 23)
- PPSV14 (Pneumo 14)
- By Target Population
- Adults (>= 65 years)
- Children (< 5 years)
- High-Risk Adults (18-64 years)
- By Route of Administration
- Intramuscular
- Subcutaneous
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
- Key Players Insights
- Pfizer Inc.
- Merck & Co., Inc.
- GlaxoSmithKline plc (GSK)
- Sanofi
- CSL Limited
- Serum Institute of India Pvt. Ltd.
- Vaxcyte, Inc.
- Astellas Pharma Inc.
- Panacea Biotec Ltd.
- Walvax Biotechnology Co., Ltd.
- Beijing Minhai Biotechnology Co., Ltd.
- Merck KGaA
- Takeda Pharmaceutical Company Limited
- AbbVie Inc.
- Novartis AG
- Johnson & Johnson
- Biovac
- Bharat Biotech
- Inovio Pharmaceuticals, Inc.
- Hilleman Laboratories Pvt. Ltd
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Pneumococcal Vaccines Market, By Vaccine Type
- Global Pneumococcal Vaccines Market, By Target Population
- Global Pneumococcal Vaccines Market, By Route of Administration
- Global Pneumococcal Vaccines Market, By Distribution Channel
- Global Pneumococcal Vaccines Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Pneumococcal Vaccines Market, By Vaccine Type, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Pneumococcal Conjugate Vaccines (PCVs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- PCV13 (Prevnar 13/Prevenar 13)
- PCV10 (Synflorix)
- PCV7 (Prevnar/Prevenar)
- Pneumococcal Polysaccharide Vaccines (PPVs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- PPSV23 (Pneumovax 23)
- PPSV14 (Pneumo 14)
5. Global Pneumococcal Vaccines Market, By Target Population, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Adults (>= 65 years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Children (< 5 years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- High-Risk Adults (18-64 years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
6. Global Pneumococcal Vaccines Market, By Route of Administration, 2019-2031, (USD Bn)
- Intramuscular
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
7. Global Pneumococcal Vaccines Market, By Distribution Channel, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
8. Global Pneumococcal Vaccines Market, By Region, 2019 - 2031, (USD Bn)
- Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2020- 2031, (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Vaccine Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Target Population, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Vaccine Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Target Population, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Vaccine Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Target Population, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Vaccine Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Target Population, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Vaccine Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Target Population, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Vaccine Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Target Population, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country/Sub-region, 2019 - 2031, (USD Bn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline plc (GSK)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- CSL Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Serum Institute of India Pvt. Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Vaxcyte, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Panacea Biotec Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Walvax Biotechnology Co., Ltd.
- Beijing Minhai Biotechnology Co., Ltd.
- Merck KGaA
- Takeda Pharmaceutical Company Limited
- AbbVie Inc.
- Novartis AG
- Johnson & Johnson
- Biovac
- Bharat Biotech
- Inovio Pharmaceuticals, Inc.
- Hilleman Laboratories Pvt. Ltd
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us
